The protection conferred by chelation therapy in post-MI diabetics might be replicated by high-dose zinc supplementation

Medical Hypotheses

Volumn 84, Issue 5, 2015, Pages 451-455

  McCarty, Mark F ^a   DiNicolantonio, James J ^b  

^a Catalytic Longevity   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ASCORBIC ACID; C REACTIVE PROTEIN; CADMIUM; COPPER; HISTIDINE; INTERLEUKIN 6; METALLOTHIONEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIENTINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ZINC;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHELATION THERAPY; CLINICAL STUDY; DETOXIFICATION; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIETARY INTAKE; DRUG MEGADOSE; ENZYME ACTIVITY; GLYCEMIC CONTROL; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MAINTENANCE THERAPY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENICITY; PHLEBOTOMY; PROTEIN EXPRESSION; RISK REDUCTION; TISSUE INJURY; VITAMIN SUPPLEMENTATION; WILSON DISEASE; ZINC BLOOD LEVEL; ABSORPTION; COMPLICATION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG EFFECTS; FEMALE; MYOCARDIAL INFARCTION; OXIDATION REDUCTION REACTION; PROCEDURES;

RODENTIA;

ABSORPTION, PHYSICOCHEMICAL; CHELATION THERAPY; COPPER; DIABETES COMPLICATIONS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; ZINC;

EID: 84925786077     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.01.038     Document Type: Article

References (95)

1. Escolar E., Lamas G.A., Mark D.B., et al. The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes 2013.
2. Frizzell N., Baynes J.W. Chelation therapy: overlooked in the treatment and prevention of diabetes complications?. Future Med Chem 2013, 5(10):1075-1078.
3. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114(6):597-605.
4. Nagai R., Ikeda K., Higashi T., et al. Hydroxyl radical mediates N epsilon-(carboxymethyl)lysine formation from Amadori product. Biochem Biophys Res Commun 1997, 234(1):167-172.
5. Paneni F., Cosentino F. Advanced glycation endproducts and plaque instability: a link beyond diabetes. Eur Heart J 2013.
6. Zacharski L.R., Chow B.K., Howes P.S., et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007, 297(6):603-610.
7. Inkster M.E., Cotter M.A., Cameron N.E. Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats. Free Radic Res 2002, 36(10):1091-1099.
8. Cooper G.J., Phillips A.R., Choong S.Y., et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004, 53(9):2501-2508.
9. Hamada Y., Nakashima E., Naruse K., et al. A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. J Diabetes Complications 2005, 19(6):328-334.
10. Gong D., Lu J., Chen X., et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia 2008, 51(9):1741-1751.
11. Cooper G.J., Young A.A., Gamble G.D., et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia 2009 April, 52(4):715-722.
12. Baynes J.W., Murray D.B. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diabetes Res 2009, 2009:696378.
13. Lu J., Gong D., Choong S.Y., et al. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 2010, 53(6):1217-1226.
14. Cooper G.J. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 2011, 71(10):1281-1320.
15. Lu J., Pontre B., Pickup S., et al. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment. Cardiovasc Diabetol 2013, 12:28.
16. Moya-Olano L., Milne H.M., Robinson J.M., et al. Trientine and renin-angiotensin system blockade ameliorate progression of glomerular morphology in hypertensive experimental diabetic nephropathy. Pathol Int 2011, 61(11):652-661.
17. Saxena A.K., Saxena P., Wu X., Obrenovich M., Weiss M.F., Monnier V.M. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 1999, 260(2):332-338.
18. Monnier V.M. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001, 107(7):799-801.
19. Saxena P., Saxena A.K., Cui X.L., Obrenovich M., Gudipaty K., Monnier V.M. Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products. Invest Ophthalmol Vis Sci 2000, 41(6):1473-1481.
20. Eaton J.W., Qian M. Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy. Mol Cell Biochem 2002, 234-235(1-2):135-142.
21. Schilsky M.L. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?. Curr Gastroenterol Rep 2001, 3(1):54-59.
22. Sullivan V.K., Burnett F.R., Cousins R.J. Metallothionein expression is increased in monocytes and erythrocytes of young men during zinc supplementation. J Nutr 1998, 128(4):707-713.
23. Cao J., Cousins R.J. Metallothionein mRNA in monocytes and peripheral blood mononuclear cells and in cells from dried blood spots increases after zinc supplementation of men. J Nutr 2000, 130(9):2180-2187.
24. Aydemir T.B., Blanchard R.K., Cousins R.J. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc Natl Acad Sci USA 2006, 103(6):1699-1704.
25. Fischer P.W., Giroux A., L'Abbe M.R. Effects of zinc on mucosal copper binding and on the kinetics of copper absorption. J Nutr 1983, 113(2):462-469.
26. Yuzbasiyan-Gurkan V., Grider A., Nostrant T., Cousins R.J., Brewer G.J. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992, 120(3):380-386.
27. Brewer G.J., Dick R.D., Johnson V.D., Brunberg J.A., Kluin K.J., Fink J.K. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998, 132(4):264-278.
28. Tachibana H., Ogawa D., Sogawa N., et al. Metallothionein deficiency exacerbates diabetic nephropathy in streptozotocin-induced diabetic mice. Am J Physiol Renal Physiol 2013.
29. Islam M.S., Loots D.T. Diabetes, metallothionein, and zinc interactions: a review. BioFactors 2007, 29(4):203-212.
30. Chen H., Carlson E.C., Pellet L., Moritz J.T., Epstein P.N. Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 2001, 50(9):2040-2046.
31. Liang Q., Carlson E.C., Donthi R.V., Kralik P.M., Shen X., Epstein P.N. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002, 51(1):174-181.
32. Wang J., Song Y., Elsherif L., et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006, 113(4):544-554.
33. Maret W. A role for metallothionein in the pathogenesis of diabetes and its cardiovascular complications. Mol Genet Metab 2008, 94(1):1-3.
34. Zheng S., Carlson E.C., Yang L., Kralik P.M., Huang Y., Epstein P.N. Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol 2008, 19(11):2077-2085.
35. Zhou G., Li X., Hein D.W., et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 2008, 52(8):655-666.
36. Ohly P., Wang Z., Abel J., Gleichmann H. Zincsulphate induced metallothionein in pancreatic islets and protected against the diabetogenic toxin streptozotocin. Talanta 1998, 46(2):355-359.
37. Wang Y., Feng W., Xue W., et al. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 2009, 58(6):1391-1402.
38. Tang Y., Yang Q., Lu J., et al. Zinc supplementation partially prevents renal pathological changes in diabetic rats. J Nutr Biochem 2010, 21(3):237-246.
39. Bellomo E.A., Meur G., Rutter G.A. Glucose regulates free cytosolic Zn(2)(+) concentration, Slc39 (ZiP), and metallothionein gene expression in primary pancreatic islet beta-cells. J Biol Chem 2011, 286(29):25778-25789.
40. Park L., Min D., Kim H., et al. Tat-enhanced delivery of metallothionein can partially prevent the development of diabetes. Free Radic Biol Med 2011, 51(9):1666-1674.
41. Park L., Min D., Kim H., Park J., Choi S., Park Y. The combination of metallothionein and superoxide dismutase protects pancreatic beta cells from oxidative damage. Diabetes Metab Res Rev 2011, 27(8):802-808.
42. Min D., Kim H., Park L., et al. Amelioration of diabetic neuropathy by TAT-mediated enhanced delivery of metallothionein and SOD. Endocrinology 2012, 153(1):81-91.
43. Xue W., Liu Y., Zhao J., Cai L., Li X., Feng W. Activation of HIF-1 by metallothionein contributes to cardiac protection in the diabetic heart. Am J Physiol Heart Circ Physiol 2012, 302(12):H2528-H2535.
44. Carlson E.C., Chhoun J.M., Laturnus D.I., et al. Podocyte-specific overexpression of metallothionein mitigates diabetic complications in the glomerular filtration barrier and glomerular histoarchitecture: a transmission electron microscopy stereometric analysis. Diabetes Metab Res Rev 2013, 29(2):113-124.
45. Li B., Tan Y., Sun W., Fu Y., Miao L., Cai L. The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy. Toxicol Mech Methods 2013, 23(1):27-33.
46. Ozcelik D., Naziroglu M., Tuncdemir M., Celik O., Ozturk M., Flores-Arce M.F. Zinc supplementation attenuates metallothionein and oxidative stress changes in kidney of streptozotocin-induced diabetic rats. Biol Trace Elem Res 2012, 150(1-3):342-349.
47. Cong W., Ma W., Zhao T., et al. Metallothionein prevents diabetes-induced cardiac pathological changes, likely via the inhibition of succinyl-CoA:3-ketoacid coenzyme A transferase-1 nitration at Trp(374). Am J Physiol Endocrinol Metab 2013, 304(8):E826-E835.
48. Miao X., Wang Y., Sun J., et al. Zinc protects against diabetes-induced pathogenic changes in the aorta: roles of metallothionein and nuclear factor (erythroid-derived 2)-like 2. Cardiovasc Diabetol 2013, 12:54.
49. Jansen J., Karges W., Rink L. Zinc and diabetes-clinical links and molecular mechanisms. J Nutr Biochem 2009, 20(6):399-417.
50. Wang X., Li H., Fan Z., Liu Y. Effect of zinc supplementation on type 2 diabetes parameters and liver metallothionein expressions in Wistar rats. J Physiol Biochem 2012, 68(4):563-572.
51. Sun Q., van Dam R.M., Willett W.C., Hu F.B. Prospective study of zinc intake and risk of type 2 diabetes in women. Diabetes Care 2009, 32(4):629-634.
52. Vashum K.P., McEvoy M., Shi Z., et al. Is dietary zinc protective for type 2 diabetes? Results from the Australian longitudinal study on women's health. BMC Endocr Disord 2013, 13(1):40.
53. Jayawardena R., Ranasinghe P., Galappatthy P., Malkanthi R., Constantine G., Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2012, 4(1):13.
54. Capdor J., Foster M., Petocz P., Samman S. Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J Trace Elem Med Biol 2013, 27(2):137-142.
55. Faure P., Benhamou P.Y., Perard A., Halimi S., Roussel A.M. Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr 1995, 49(4):282-288.
56. Anderson R.A., Roussel A.M., Zouari N., Mahjoub S., Matheau J.M., Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 2001, 20(3):212-218.
57. Roussel A.M., Kerkeni A., Zouari N., Mahjoub S., Matheau J.M., Anderson R.A. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr 2003, 22(4):316-321.
58. Soinio M., Marniemi J., Laakso M., Pyorala K., Lehto S., Ronnemaa T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 2007, 30(3):523-528.
59. Kinlaw W.B., Levine A.S., Morley J.E., Silvis S.E., McClain C.J. Abnormal zinc metabolism in type II diabetes mellitus. Am J Med 1983, 75(2):273-277.
60. Niewoehner C.B., Allen J.I., Boosalis M., Levine A.S., Morley J.E. Role of zinc supplementation in type II diabetes mellitus. Am J Med 1986, 81(1):63-68.
61. Chen M.D., Lin P.Y., Tsou C.T., Wang J.J., Lin W.H. Selected metals status in patients with noninsulin-dependent diabetes mellitus. Biol Trace Elem Res 1995, 50(2):119-124.
62. Brzoska M.M., Moniuszko-Jakoniuk J. Interactions between cadmium and zinc in the organism. Food Chem Toxicol 2001, 39(10):967-980.
63. Bulat Z.P., Djukic-Cosic D., Malicevic Z., Bulat P., Matovic V. Zinc or magnesium supplementation modulates cd intoxication in blood, kidney, spleen, and bone of rabbits. Biol Trace Elem Res 2008, 124(2):110-117.
64. Rogalska J., Pilat-Marcinkiewicz B., Brzoska M.M. Protective effect of zinc against cadmium hepatotoxicity depends on this bioelement intake and level of cadmium exposure: a study in a rat model. Chem Biol Interact 2011, 193(3):191-203.
65. Brzoska M.M., Roszczenko A., Galazyn-Sidorczuk M., Majewska K. Zinc supplementation can protect from enhanced risk of femoral neck fracture in male rats chronically exposed to cadmium. Exp Toxicol Pathol 2011, 63(5):491-498.
66. Jarup L., Akesson A. Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol 2009, 238(3):201-208.
67. Nawrot T.S., Staessen J.A., Roels H.A., et al. Cadmium exposure in the population: from health risks to strategies of prevention. Biometals 2010, 23(5):769-782.
68. Everett C.J., Frithsen I.L. Association of urinary cadmium and myocardial infarction. Environ Res 2008, 106(2):284-286.
69. Agarwal S., Zaman T., Tuzcu E.M., Kapadia S.R. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. Angiology 2011, 62(5):422-429.
70. Lee M.S., Park S.K., Hu H., Lee S. Cadmium exposure and cardiovascular disease in the 2005 Korea National Health and Nutrition Examination Survey. Environ Res 2011, 111(1):171-176.
71. Suwazono Y., Sand S., Vahter M., et al. Benchmark dose for cadmium-induced renal effects in humans. Environ Health Perspect 2006, 114(7):1072-1076.
72. Clemons T.E., Kurinij N., Sperduto R.D. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol 2004, 122(5):716-726.
73. Prasad A.S., Beck F.W., Bao B., et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr 2007, 85(3):837-844.
74. Prasad A.S. Zinc in human health: effect of zinc on immune cells. Mol Med 2008, 14(5-6):353-357.
75. Bao B., Prasad A.S., Beck F.W., et al. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr 2010, 91(6):1634-1641.
76. Price D.L., Rhett P.M., Thorpe S.R., Baynes J.W. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001, 276(52):48967-48972.
77. Nagai R., Murray D.B., Metz T.O., Baynes J.W. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012, 61(3):549-559.
78. Naughton D.P., Knappitt J., Fairburn K., Gaffney K., Blake D.R., Grootveld M. Detection and investigation of the molecular nature of low-molecular-mass copper ions in isolated rheumatoid knee-joint synovial fluid. FEBS Lett 1995, 361(2-3):167-172.
79. Brigelius R., Spottl R., Bors W., Lengfelder E., Saran M., Weser U. Superoxide dismutase activity of low molecular weight Cu2 plus-chelates studied by pulse radiolysis. FEBS Lett 1974, 47(1):72-75.
80. Waslen T.A., Houston C.S., Tchang S. Menkes' kinky-hair disease: radiologic findings in a patient treated with copper histidinate. Can Assoc Radiol J 1995, 46(2):114-117.
81. Lee Y.T., Hsu C.C., Lin M.H., Liu K.S., Yin M.C. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005, 513(1-2):145-150.
82. Feng R.N., Niu Y.C., Sun X.W., et al. Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. Diabetologia 2013, 56(5):985-994.
83. Niu Y.C., Feng R.N., Hou Y., et al. Histidine and arginine are associated with inflammation and oxidative stress in obese women. Br J Nutr 2012, 108(1):57-61.
84. Mihalik SJ, Michaliszyn SF, de las HJ et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care 2012; 35(3):605-11.
85. Watanabe M., Suliman M.E., Qureshi A.R., et al. Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. Am J Clin Nutr 2008, 87(6):1860-1866.
86. Hipkiss A.R. Would carnosine or a carnivorous diet help suppress aging and associated pathologies?. Ann N Y Acad Sci 2006, 1067:369-374.
87. Boldyrev A.A., Aldini G., Derave W. Physiology and pathophysiology of carnosine. Physiol Rev 2013, 93(4):1803-1845.
88. Everaert I., Taes Y., De H.E., et al. Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans. Am J Physiol Renal Physiol 2012, 302(12):F1537-F1544.
89. Kimura K., Nakamura Y., Inaba Y., et al. Histidine augments the suppression of hepatic glucose production by central insulin action. Diabetes 2013, 62(7):2266-2277.
90. Buettner G.R., Jurkiewicz B.A. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 1996, 145(5):532-541.
91. Chen Q., Espey M.G., Sun A.Y., et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007, 104(21):8749-8754.
92. Ma Y., Chapman J., Levine M., Polireddy K., Drisko J., Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014 5;6(222):222ra18.
93. Roussel A.M., Hininger-Favier I., Waters R.S., Osman M., Fernholz K., Anderson R.A. EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation. Altern Med Rev 2009, 14(1):56-61.
94. Lee D.H., Folsom A.R., Harnack L., Halliwell B., Jacobs D.R. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?. Am J Clin Nutr 2004, 80(5):1194-1200.
95. Osganian S.K., Stampfer M.J., Rimm E., et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol 2003, 42(2):246-252.